BidaskClub upgraded shares of NeoGenomics (NASDAQ:NEO) from a sell rating to a hold rating in a research note released on Thursday.

A number of other research analysts have also recently commented on NEO. ValuEngine raised shares of NeoGenomics from a buy rating to a strong-buy rating in a research report on Thursday. Needham & Company LLC assumed coverage on shares of NeoGenomics in a research report on Thursday, January 3rd. They set a buy rating and a $14.00 target price on the stock. Zacks Investment Research raised shares of NeoGenomics from a hold rating to a strong-buy rating and set a $21.00 price target on the stock in a report on Saturday, November 3rd. Raymond James reaffirmed a buy rating and issued a $24.00 price target on shares of NeoGenomics in a report on Tuesday, December 4th. Finally, First Analysis set a $16.00 price target on shares of NeoGenomics and gave the company a buy rating in a report on Tuesday, September 18th. Two research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $19.33.

NEO stock traded up $0.08 during midday trading on Thursday, reaching $15.36. 18,315,257 shares of the company’s stock traded hands, compared to its average volume of 3,990,308. The stock has a market cap of $1.40 billion, a price-to-earnings ratio of 256.00 and a beta of 0.43. The company has a quick ratio of 3.98, a current ratio of 4.13 and a debt-to-equity ratio of 0.32. NeoGenomics has a fifty-two week low of $7.08 and a fifty-two week high of $19.04.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings results on Tuesday, October 30th. The medical research company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. The firm had revenue of $69.10 million for the quarter, compared to analysts’ expectations of $66.13 million. NeoGenomics had a net margin of 1.70% and a return on equity of 2.63%. NeoGenomics’s revenue was up 16.8% compared to the same quarter last year. During the same period in the previous year, the company posted $0.01 earnings per share. On average, equities analysts forecast that NeoGenomics will post 0.11 EPS for the current fiscal year.

In other NeoGenomics news, Director Kevin C. Johnson sold 66,007 shares of the business’s stock in a transaction on Friday, November 9th. The shares were sold at an average price of $17.03, for a total transaction of $1,124,099.21. Following the completion of the sale, the director now owns 97,873 shares in the company, valued at $1,666,777.19. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Kevin C. Johnson purchased 26,000 shares of the stock in a transaction dated Friday, December 21st. The shares were purchased at an average price of $11.60 per share, with a total value of $301,600.00. Following the transaction, the director now directly owns 103,866 shares of the company’s stock, valued at approximately $1,204,845.60. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 15,829,788 shares of company stock valued at $213,793,738. 12.20% of the stock is owned by insiders.

Several institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc grew its position in shares of NeoGenomics by 10.0% during the third quarter. Legal & General Group Plc now owns 10,559 shares of the medical research company’s stock worth $162,000 after acquiring an additional 963 shares during the last quarter. Vanguard Group Inc lifted its holdings in NeoGenomics by 24.0% in the third quarter. Vanguard Group Inc now owns 3,839,641 shares of the medical research company’s stock worth $58,939,000 after purchasing an additional 743,245 shares during the period. Federated Investors Inc. PA lifted its holdings in NeoGenomics by 36.0% in the third quarter. Federated Investors Inc. PA now owns 841,883 shares of the medical research company’s stock worth $12,923,000 after purchasing an additional 222,983 shares during the period. Marshall Wace North America L.P. lifted its holdings in NeoGenomics by 0.4% in the third quarter. Marshall Wace North America L.P. now owns 220,059 shares of the medical research company’s stock worth $3,378,000 after purchasing an additional 934 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in NeoGenomics by 24.0% in the third quarter. Vanguard Group Inc. now owns 3,839,641 shares of the medical research company’s stock worth $58,939,000 after purchasing an additional 743,245 shares during the period. Institutional investors and hedge funds own 83.22% of the company’s stock.

About NeoGenomics

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.

Recommended Story: How can you know how many shares are floating?

Analyst Recommendations for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.